Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Rigel Pharmaceuticals Inc

Healthcare US RIGL

29.93USD
-0.32(1.06%)

Last update at 2026-06-05T20:00:00Z

Day Range

29.7430.69
LowHigh

52 Week Range

0.711.77
LowHigh

Fundamentals

  • Previous Close 30.25
  • Market Cap163.37M
  • Volume498096
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-14.55100M
  • Revenue TTM119.25M
  • Revenue Per Share TTM0.68
  • Gross Profit TTM 53.72M
  • Diluted EPS TTM-0.11

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -58.57300M -17.30900M -29.74400M -66.89400M -70.48000M
Minority interest - - - - -
Net income -61.59600M -17.91400M -30.39100M -66.54600M -70.48000M
Selling general administrative 112.45M 91.89M 76.60M 74.59M 70.00M
Selling and marketing expenses - - - - -
Gross profit 118.49M 148.15M 107.73M 58.38M 44.22M
Reconciled depreciation 1.00M 1.16M 0.71M 0.68M 0.59M
Ebit -54.23000M -8.97500M -28.97300M -69.09100M -73.27700M
Ebitda -53.54600M -8.92800M -28.39100M -66.55900M -72.68300M
Depreciation and amortization 0.68M 0.05M 0.58M 2.53M 0.59M
Non operating income net other 0.68M 0.05M 0.58M 2.53M 2.20M
Operating income -54.23000M -8.97500M -28.97300M -69.09100M -72.68300M
Other operating expenses 174.47M 158.21M 137.59M 128.38M 117.19M
Interest expense 3.71M 4.86M 1.35M 0.34M 0.00000M
Tax provision 0.00000M 0.60M - - -
Interest income 0.68M 0.05M 0.58M 2.53M 2.20M
Net interest income -3.02300M -4.81300M -0.77100M 2.20M 2.20M
Extraordinary items - - - - -
Non recurring 1.32M 3.52M - - -
Other items - - - - -
Income tax expense 3.02M 0.60M 0.65M -0.34800M 2.20M
Total revenue 120.24M 149.24M 108.62M 59.29M 44.51M
Total operating expenses 172.72M 157.13M 136.70M 127.47M 116.91M
Cost of revenue 1.75M 1.08M 0.90M 0.91M 0.29M
Total other income expense net -4.34300M -8.33400M -0.77100M 2.20M 2.20M
Discontinued operations - - - - -
Net income from continuing ops -58.57300M -17.91400M -29.74400M -66.89400M -70.48000M
Net income applicable to common shares -58.57300M -17.91400M -29.74400M -66.89400M -70.48000M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 117.22M 134.28M 167.33M 110.38M 147.57M
Intangible assets 13.88M 14.95M - - -
Earning assets - - - - -
Other current assets 6.26M 8.26M 7.41M 14.04M 9.46M
Total liab 145.87M 147.90M 136.95M 76.35M 93.75M
Total stockholder equity -28.64400M -13.61600M 30.37M 34.03M 53.81M
Deferred long term liab - - - - -
Other current liab 21.16M 28.06M 47.27M 25.50M 21.50M
Common stock 0.17M 0.17M 0.17M 0.17M 0.17M
Capital stock 0.17M 0.17M 0.17M 0.17M 0.17M
Retained earnings -1407.55000M -1382.45900M -1323.88600M -1305.97200M -1276.22800M
Other liab - - 52.73M 5.04M 6.50M
Good will - - - - -
Other assets - 0.64M 0.97M 0.82M 0.70M
Cash 32.79M 24.46M 18.89M 30.37M 22.52M
Cash and equivalents - - - - -
Total current liabilities 53.27M 65.21M 63.55M 40.84M 58.21M
Current deferred revenue 17.04M 13.51M 2.60M 3.02M 25.29M
Net debt 27.79M 17.09M 11.68M 8.71M 13.79M
Short term debt 7.92M 1.13M 9.89M 8.62M 7.27M
Short long term debt 7.23M - - - -
Short long term debt total 60.58M 41.55M 30.57M 39.09M 36.31M
Other stockholder equity 1378.72M 1368.82M 1354.19M 1339.83M 1329.85M
Property plant equipment - 0.86M 11.89M 2.68M 2.16M
Total current assets 99.27M 115.90M 154.47M 88.98M 119.00M
Long term investments - - - - -
Net tangible assets - -28.56500M 30.37M 44.68M 74.45M
Short term investments 24.15M 33.75M 106.08M 26.95M 75.56M
Net receivables 30.55M 40.32M 15.47M 15.97M 10.11M
Long term debt 52.37M 39.45M 19.91M 19.82M 9.81M
Inventory 5.52M 9.12M 6.62M 1.64M 1.35M
Accounts payable 7.14M 22.51M 3.79M 3.71M 4.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00800M -0.15300M -0.10200M -0.00400M 0.02M
Additional paid in capital - - - - -
Common stock total equity - 0.17M 0.17M 0.17M 0.17M
Preferred stock total equity - - - - -
Retained earnings total equity - -1382.45900M -1323.88600M -1305.97200M -1276.22800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.06M 0.64M 0.97M 0.82M 0.70M
Deferred long term asset charges - - - - -
Non current assets total 17.96M 18.38M 12.86M 21.39M 28.56M
Capital lease obligations 0.98M 2.10M 10.65M 19.27M 26.50M
Long term debt total - 39.45M 19.91M 19.82M 9.81M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 72.33M -79.40900M 48.73M -22.20100M 26.07M
Change to liabilities -3.54100M -0.38100M 3.42M -1.05300M 11.09M
Total cashflows from investing activities 72.78M -80.03600M 47.47M -23.65600M 24.96M
Net borrowings 19.54M 19.54M 9.97M 9.79M 9.79M
Total cash from financing activities 6.55M 62.67M 12.57M 11.37M 71.89M
Change to operating activities -4.38500M 14.47M -0.37400M 1.04M 2.85M
Net income -58.57300M -17.91400M -29.74400M -66.89400M -70.48000M
Change in cash 5.57M -11.48300M 7.85M -53.80100M 38.03M
Begin period cash flow 18.89M 30.37M 22.52M 76.32M 38.29M
End period cash flow 24.46M 18.89M 30.37M 22.52M 76.32M
Total cash from operating activities -73.75800M 5.88M -52.18500M -41.51000M -58.82600M
Issuance of capital stock - - 0.00000M 0.00000M 67.16M
Depreciation 1.00M 1.16M 0.71M 0.68M 0.59M
Other cashflows from investing activities 0.89M - - -22.20100M 26.07M
Dividends paid - - - - -
Change to inventory -2.37700M -4.87500M -0.12600M -0.36600M -0.83900M
Change to account receivables -24.84800M 0.50M -5.86200M -6.03400M -4.07700M
Sale purchase of stock 2.12M 4.78M 2.60M 1.58M 71.89M
Other cashflows from financing activities 4.43M 62.67M 12.57M 11.37M 4.73M
Change to netincome 13.07M 12.91M 7.30M 9.12M 7.70M
Capital expenditures 0.45M 0.63M 1.26M 1.46M 1.11M
Change receivables -24.84800M 0.50M -5.86200M -6.03400M -4.07700M
Cash flows other operating 1.58M 5.63M -27.75600M 24.11M -2.05100M
Exchange rate changes - - - - -
Cash and cash equivalents changes 5.57M -11.48300M 7.85M -53.80100M 38.03M
Change in working capital -29.04900M 9.72M -30.32200M 16.66M 4.12M
Stock based compensation 12.38M 9.49M 7.30M 9.12M 7.70M
Other non cash items 0.48M 3.14M -0.12200M -1.07300M -0.76600M
Free cash flow -74.20800M 5.25M -53.44700M -42.96500M -59.93200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RIGL
Rigel Pharmaceuticals Inc		 -0.32 1.06% 29.93 - - 1.82 31.64 1.82 -12.5068
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Rigel Pharmaceuticals Inc

611 Gateway Blvd, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Mr. Raul R. Rodriguez Pres, CEO & Director 1961
Mr. Dean L. Schorno CPA Exec. VP & CFO 1963
Dr. Wolfgang Dummer M.D., Ph.D. Exec. VP & Chief Medical Officer 1966
Mr. David A. Santos Exec. VP & Chief Commercial Officer 1963
Mr. Joseph Lasaga Exec. VP of Corp. Devel. 1975
Ms. Julie Patel Sr. VP of HR NA
Dr. Esteban S. Masuda Exec. VP of Research 1962
Mr. Tarek Sallam VP of Marketing NA
Mr. Raul R. Rodriguez President, CEO & Director 1961
Mr. Dean L. Schorno CPA Executive VP & CFO 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions